{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,23]],"date-time":"2026-02-23T18:26:40Z","timestamp":1771871200396,"version":"3.50.1"},"reference-count":31,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2014,2]]},"DOI":"10.1097\/jcp.0000000000000060","type":"journal-article","created":{"date-parts":[[2013,10,30]],"date-time":"2013-10-30T13:10:54Z","timestamp":1383138654000},"page":"47-56","source":"Crossref","is-referenced-by-count":61,"title":["A Phase III, Double-Blind, Placebo-Controlled, Flexible-Dose Study of Levomilnacipran Extended-Release in Patients With Major Depressive Disorder"],"prefix":"10.1097","volume":"34","author":[{"given":"Angelo","family":"Sambunaris","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anjana","family":"Bose","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carl P.","family":"Gommoll","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Changzheng","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"William M.","family":"Greenberg","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David V.","family":"Sheehan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"issue":"11","key":"R1-11-20210128","doi-asserted-by":"crossref","first-page":"e442","DOI":"10.1371\/journal.pmed.0030442","article-title":"Projections of global mortality and burden of disease from 2002 to 2030.","volume":"3","author":"Mathers","year":"2006","journal-title":"PLoS Med"},{"issue":"suppl 1","key":"R2-11-20210128","first-page":"21","article-title":"Improvement of the noradrenergic symptom cluster following treatment with milnacipran.","volume":"7","author":"Kasper","year":"2011","journal-title":"Neuropsychiatr Dis Treat"},{"issue":"2","key":"R4-11-20210128","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/S0006-3223(01)01291-4","article-title":"Does psychosocial functioning improve independent of depressive symptoms A comparison of nefazodone, psychotherapy, and their combination.","volume":"51","author":"Hirschfeld","year":"2002","journal-title":"Biol Psychiatry"},{"issue":"3","key":"R5-11-20210128","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1016\/j.cpr.2009.01.005","article-title":"The importance of functional impairment to mental health outcomes: a case for reassessing our goals in depression treatment research.","volume":"29","author":"McKnight","year":"2009","journal-title":"Clin Psychol Rev"},{"key":"R6-11-20210128","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1016\/j.neuropharm.2013.02.024","article-title":"Levomilnacipran (F2695), a norepinephrine-preferring SNRI: profile in vitro and in models of depression and anxiety.","volume":"70","author":"Auclair","year":"2013","journal-title":"Neuropharmacology"},{"issue":"1","key":"R7-11-20210128","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/S0163-8343(00)00115-8","article-title":"Role of serotonin and noradrenaline in social dysfunction: a review of data on reboxetine and the Social Adaptation Self-evaluation Scale (SASS).","volume":"23","author":"Keller","year":"2001","journal-title":"Gen Hosp Psychiatry"},{"issue":"suppl E1","key":"R8-11-20210128","first-page":"4","article-title":"Relationship of neurotransmitters to the symptoms of major depressive disorder.","volume":"69","author":"Nutt","year":"2008","journal-title":"J Clin Psychiatry"},{"issue":"9","key":"R9-11-20210128","doi-asserted-by":"crossref","first-page":"1723","DOI":"10.1124\/dmd.112.045120","article-title":"Excretion and metabolism of milnacipran in humans after oral administration of milnacipran hydrochloride.","volume":"40","author":"Li","year":"2012","journal-title":"Drug Metab Dispos"},{"issue":"4","key":"R12-11-20210128","doi-asserted-by":"crossref","first-page":"363","DOI":"10.4088\/JCP.12m08141","article-title":"The efficacy and safety of levomilnacipran sustained release in moderate to severe major depressive disorder: a randomized, double-blind, placebo-controlled, proof-of-concept study.","volume":"74","author":"Montgomery","year":"2013","journal-title":"J Clin Psychiatry"},{"issue":"3","key":"R13-11-20210128","doi-asserted-by":"crossref","first-page":"242","DOI":"10.4088\/JCP.12m08197","article-title":"The efficacy and safety of levomilnacipran SR 40 mg, 80 mg, or 120 mg in major depressive disorder: a phase III, randomized, double-blind, placebo-controlled study.","volume":"74","author":"Asnis","year":"2013","journal-title":"J Clin Psychiatry"},{"issue":"suppl 20","key":"R16-11-20210128","first-page":"22","article-title":"The Mini-International Neuropsychiatric Interview (M.I.N.I.): the development and validation of a structured diagnostic psychiatric interview for DSM-IV and ICD-10.","volume":"59","author":"Sheehan","year":"1998","journal-title":"J Clin Psychiatry"},{"key":"R17-11-20210128","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1192\/bjp.134.4.382","article-title":"A new depression scale designed to be sensitive to change.","volume":"134","author":"Montgomery","year":"1979","journal-title":"Br J Psychiatry"},{"issue":"12","key":"R18-11-20210128","doi-asserted-by":"crossref","first-page":"1266","DOI":"10.1176\/appi.ajp.2011.10111704","article-title":"The Columbia-Suicide Severity Rating Scale: initial validity and internal consistency findings from three multisite studies with adolescents and adults.","volume":"168","author":"Posner","year":"2011","journal-title":"Am J Psychiatry"},{"issue":"suppl 3","key":"R19-11-20210128","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1097\/00004850-199606003-00015","article-title":"The measurement of disability.","volume":"11","author":"Sheehan","year":"1996","journal-title":"Int Clin Psychopharmacol"},{"key":"R20-11-20210128","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1136\/jnnp.23.1.56","article-title":"A rating scale for depression.","volume":"23","author":"Hamilton","year":"1960","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"7","key":"R22-11-20210128","doi-asserted-by":"crossref","first-page":"1321","DOI":"10.1023\/B:QURE.0000037502.64077.4d","article-title":"The development and psychometric evaluation of the Motivation and Energy Inventory (MEI).","volume":"13","author":"Fehnel","year":"2004","journal-title":"Qual Life Res"},{"issue":"4","key":"R23-11-20210128","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1007\/s002130000533","article-title":"The memory enhancing effects of a Ginkgo bilobaPanax ginseng combination in healthy middle-aged volunteers.","volume":"152","author":"Wesnes","year":"2000","journal-title":"Psychopharmacology (Berl)"},{"key":"R24-11-20210128","first-page":"211","article-title":"The use of analogue scales in rating subjective feelings Br J Med Psychol.","volume":"47","author":"Bond","year":"1974","journal-title":""},{"issue":"3","key":"R25-11-20210128","doi-asserted-by":"crossref","first-page":"983","DOI":"10.2307\/2533558","article-title":"Small sample inference for fixed effects from restricted maximum likelihood.","volume":"53","author":"Kenward","year":"1997","journal-title":"Biometrics"},{"issue":"1","key":"R26-11-20210128","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1093\/biomet\/90.1.53","article-title":"Pattern-mixture models with proper time dependence.","volume":"90","author":"Kenward","year":"2003","journal-title":"Biometrika"},{"issue":"2","key":"R27-11-20210128","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1097\/YIC.0b013e3282f2b4d6","article-title":"Assessing treatment effects in clinical trials with the discan metric of the Sheehan Disability Scale.","volume":"23","author":"Sheehan","year":"2008","journal-title":"Int Clin Psychopharmacol"},{"issue":"3-4","key":"R28-11-20210128","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/j.jpsychires.2006.05.008","article-title":"The burden of severe depression: a review of diagnostic challenges and treatment alternatives.","volume":"41","author":"Nemeroff","year":"2007","journal-title":"J Psychiatr Res"},{"issue":"7","key":"R31-11-20210128","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1586\/ern.09.53","article-title":"Strategies to enhance the therapeutic efficacy of antidepressants: targeting residual symptoms.","volume":"9","author":"Kurian","year":"2009","journal-title":"Expert Rev Neurother"},{"issue":"6","key":"R32-11-20210128","doi-asserted-by":"crossref","first-page":"850","DOI":"10.4088\/JCP.v67n0601","article-title":"Are all antidepressants really the same The case of fluoxetine: a systematic review.","volume":"67","author":"Cipriani","year":"2006","journal-title":"J Clin Psychiatry"},{"issue":"2","key":"R33-11-20210128","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1097\/YIC.0b013e328341bb5f","article-title":"Assessing remission in major depressive disorder and generalized anxiety disorder clinical trials with the discan metric of the Sheehan disability scale.","volume":"26","author":"Sheehan","year":"2011","journal-title":"Int Clin Psychopharmacol"},{"issue":"2","key":"R34-11-20210128","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1016\/0165-0327(88)90060-2","article-title":"MAOI treatment response: multiaxial assessment.","volume":"14","author":"Giller","year":"1988","journal-title":"J Affect Disord"},{"issue":"10","key":"R35-11-20210128","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1001\/archpsyc.1992.01820100005001","article-title":"Treatments of depression and the functional capacity to work.","volume":"49","author":"Mintz","year":"1992","journal-title":"Arch Gen Psychiatry"},{"issue":"5","key":"R36-11-20210128","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1001\/archpsyc.1973.01750350039008","article-title":"Social adjustment and depression. A longitudinal study.","volume":"28","author":"Paykel","year":"1973","journal-title":"Arch Gen Psychiatry"},{"issue":"6","key":"R37-11-20210128","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1001\/archpsyc.1974.01760120033006","article-title":"Treatment effects on the social adjustment of depressed patients.","volume":"30","author":"Weissman","year":"1974","journal-title":"Arch Gen Psychiatry"},{"issue":"23","key":"R38-11-20210128","doi-asserted-by":"crossref","first-page":"3152","DOI":"10.1001\/jama.289.23.3152","article-title":"Past, present, and future directions for defining optimal treatment outcome in depression: remission and beyond.","volume":"289","author":"Keller","year":"2003","journal-title":"JAMA"},{"issue":"9","key":"R39-11-20210128","doi-asserted-by":"crossref","first-page":"732","DOI":"10.1017\/S1092852900019726","article-title":"SNRIs: their pharmacology, clinical efficacy, and tolerability in comparison with other classes of antidepressants.","volume":"10","author":"Stahl","year":"2005","journal-title":"CNS Spectr"}],"container-title":["Journal of Clinical Psychopharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/JCP.0000000000000060","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,5,14]],"date-time":"2021-05-14T01:46:15Z","timestamp":1620956775000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00004714-201402000-00011"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,2]]},"references-count":31,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2014]]}},"URL":"https:\/\/doi.org\/10.1097\/jcp.0000000000000060","relation":{},"ISSN":["0271-0749"],"issn-type":[{"value":"0271-0749","type":"print"}],"subject":[],"published":{"date-parts":[[2014,2]]}}}